ClinicalTrials.gg
Active, not recruitingNCT02962414Updated Nov 12, 2026

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

A Phase 3 interventional study of everolimus in Tuberous Sclerosis Complex, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 68 sites in 18 countries. Open to participants aged 2 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Updated Nov 12, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
206
Allocation
Not applicable
Ages
2 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing everolimus in Tuberous Sclerosis — none open to participants now, 1 under way, 1 of them phase 3. Everolimus · Tuberous Sclerosis.

Enrollment
2nd of 17
206 · median 36
Started
2017
the only one that year
Phase 3
4 of 17
none open now
Registered
15th of 17
by date
Lead sponsor
6 of 17
Novartis Pharmaceuticals

Among the 17 studies testing everolimus in Tuberous Sclerosis, this one is the 2nd largest by enrollment, is the only one that started in 2017, is one of 4 in phase 3, and was the 15th registered.

Tuberous Sclerosis

115 studies on the registry are indexed under Tuberous Sclerosis; 27 are open to participants now.

Browse Tuberous Sclerosis studies →

Open to participants now

None of the 17 studies testing everolimus in Tuberous Sclerosis is open now. The open studies under Tuberous Sclerosis, anywhere →

About everolimus

Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 21 Tuberous Sclerosis studies recruiting now, 10 (48%) set no upper age limit and 8 (38%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 2 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing everolimus in Tuberous Sclerosis as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety in patients with TSC and refractory seizures who are currently receiving everolimus treatment in the Novartis-sponsored EXIST-3 study and who are determined to be benefiting from continued treatment as judged by the investigator at the completion of EXIST-3

Read the detailed description

This is a multi-center, open label study to evaluate the long term safety of everolimus in patients with TSC and refractory seizures currently being treated in the Novartis-sponsored study EXIST-3 study and are judged by their parent study investigator as benefiting from the current study treatment. The study is expected to remain open for approximately 10 years (or until 31-Dec-2022 in the UK) from First Patient First Visit (FPFV).

Patients will continue to be treated in this study until they are no longer benefiting from their everolimus treatment as judged by the Investigator or until one of the protocol defined discontinuation criteria is met or everolimus becomes commercially available according to local regulations.

03

Conditions studied

  • Tuberous Sclerosis Complex

Keywords

  • Everolimus
  • Tuberous sclerosis complex
  • TSC
  • Refractory seizure
  • Roll over study
  • Long term safety
  • PASS
04

Who can participate

Ages eligible
2 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patient is currently enrolled in the Novartis-sponsored EXIST-3 study, receiving everolimus, and has fulfilled all its requirements
  • Patient is currently benefiting from treatment with everolimus, as determined by the Investigator.
  • Patient has demonstrated compliance, as assessed by the Investigator,with the parent study protocol requirements.
  • Patient is willing and able to comply with scheduled visits and treatment plans.
  • Written /adolescent assent obtained prior to enrolling into the roll-over study.

Key Exclusion Criteria:

  • Patient has been permanently discontinued from everolimus study treatment in EXIST-3 study
  • Everolimus is approved for patients with TSC and seizures and is reimbursed in the local country.
  • Patients who are receiving everolimus in combination with unapproved or experimental treatments for seizure control Anti-epileptic drug (AEDs) are allowed for the purpose of seizure control.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
206 participants (actual)

Study arms

  • Experimental
    everolimus

    everolimus, 2mg dispersible tablets

    Drug: everolimus

Interventions

  • everolimus, 2mg dispersible tablets

    Also known as: RAD001

06

What researchers measure

Primary outcomes

  1. Occurances of adverse events and serious adverse events

    The patients will be followed continuously for tolerability (i.e adverse events, serious adverse events)

    Time frame: Day 1 up to approximately 10 years

Secondary outcomes

  1. Percentage of patients with clinical benefit

    At every quarterly visit (every 12 weeks ± 2 weeks), the Investigator is required to confirm that the patients continue to have clinical benefit as per Investigator's assessment.

    Time frame: Day 1 up to approximately 10 years, assessed every 12 weeks,

07

Study locations

68 sites
  • TGen APNNA
    Phoenix, Arizona 85012, United States
  • David Geffen School of Medicine at UCLA
    Los Angeles, California 90005-1752, United States
  • UCSF Benioff Children s Hospital
    Oakland, California 94609, United States
  • Rady Children s Hospital
    San Diego, California 92123, United States
  • University of Colorado School of Medicine
    Aurora, Colorado 80045, United States
  • Connecticut Childrens Medical Cntr
    Hartford, Connecticut 06106, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Minnesota Epilepsy Group
    Saint Paul, Minnesota 55102, United States
  • Atlantic Health Morristown MC
    Morristown, New Jersey 07962, United States
  • Cinn Children Hosp Medical Center
    Cincinnati, Ohio 45229-3039, United States
  • Oregon Health Sciences University
    Portland, Oregon 97239, United States
  • Childrens Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Texas Scottish Rite Hos for Child
    Dallas, Texas 75219, United States
  • Texas Childrens Hospital
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Sydney, New South Wales 2031, Australia
  • Novartis Investigative Site
    Nedlands, Western Australia 6009, Australia
  • Novartis Investigative Site
    Brussels, 1090, Belgium
  • Novartis Investigative Site
    Brussels, 1200, Belgium
  • Novartis Investigative Site
    Ghent, 9000, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Vancouver, British Columbia V6H 3V4, Canada
  • Novartis Investigative Site
    Cali, Valle del Cauca Department 760032, Colombia
  • Novartis Investigative Site
    Amiens, 80054, France
  • Novartis Investigative Site
    Bron, 69677, France
  • Novartis Investigative Site
    Lille, 59037, France
  • Novartis Investigative Site
    Marseille, 13885, France
  • Novartis Investigative Site
    Strasbourg, 67000, France
  • Novartis Investigative Site
    Budapest, 1145, Hungary
  • Novartis Investigative Site
    Bari, BA 70124, Italy
  • Novartis Investigative Site
    Bologna, BO 40139, Italy
  • Novartis Investigative Site
    Pavia, PV 27100, Italy
  • Novartis Investigative Site
    Roma, RM 00161, Italy
  • Novartis Investigative Site
    Siena, SI 53100, Italy
  • Novartis Investigative Site
    Osaka, Osaka 5340021, Japan
  • Novartis Investigative Site
    Suita, Osaka 5650871, Japan
  • Novartis Investigative Site
    Shizuoka, Shizuoka 4208688, Japan
  • Novartis Investigative Site
    Okayama, 7008558, Japan
  • Novartis Investigative Site
    Guadalajara, Jalisco 44280, Mexico
  • Novartis Investigative Site
    Warsaw, 04-730, Poland
  • Novartis Investigative Site
    Samara, Samara Oblast 443095, Russia
  • Novartis Investigative Site
    Moscow, 119991, Russia
  • Novartis Investigative Site
    Moscow, 127412, Russia
  • Novartis Investigative Site
    Voronezh, 394024, Russia
  • Novartis Investigative Site
    Seoul, Seoul 03080, South Korea
  • Novartis Investigative Site
    Seoul, Seoul 06351, South Korea
  • Novartis Investigative Site
    Seoul, 03722, South Korea
  • Novartis Investigative Site
    Donostia / San Sebastian, Gipuzkoa 20014, Spain
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Madrid, 28009, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Seville, 41013, Spain
  • Novartis Investigative Site
    Valencia, 46026, Spain
  • Novartis Investigative Site
    Kaohsiung City, 833, Taiwan
  • Novartis Investigative Site
    Tainan, 704302, Taiwan
  • Novartis Investigative Site
    Taipei, 10002, Taiwan
  • Novartis Investigative Site
    Bangkok, 10330, Thailand
  • Novartis Investigative Site
    Bangkok, 10400, Thailand
  • Novartis Investigative Site
    Bangkok, 10700, Thailand
  • Novartis Investigative Site
    Istanbul, Fatih 34093, Turkey (Türkiye)
  • Novartis Investigative Site
    Ankara, Yenimahalle 06500, Turkey (Türkiye)
  • Novartis Investigative Site
    Birmingham, West Midlands B15 2TH, United Kingdom
  • Novartis Investigative Site
    Buckinghamshire, SL9 0RJ, United Kingdom
  • Novartis Investigative Site
    Cambridge, CB2 0QQ, United Kingdom
  • Novartis Investigative Site
    Liverpool, L12 2AP, United Kingdom
  • Novartis Investigative Site
    London, SW17 0QT, United Kingdom
  • Novartis Investigative Site
    London, WC1N 3JH, United Kingdom
  • Novartis Investigative Site
    Sheffield, S10 2TH, United Kingdom
  • Novartis Investigative Site
    York, YO31 8HE, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2017 (actual). Primary completion is estimated for Feb 2027, 114 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Dec 2026 → Feb 2027 and completion Dec 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2016
First posted
Nov 11, 2016
StartActual
Aug 23, 2017
Primary completionEst.
Feb 26, 2027was Dec 2026
CompletionEst.
Feb 26, 2027was Dec 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 3 sites removed
Show 4 added (2 South Korea, 1 Japan, 1 United Kingdom)
  • Novartis Investigative Site · Osaka, Japan
  • Novartis Investigative Site · Seoul, South Korea
  • Novartis Investigative Site · Seoul, South Korea
  • Novartis Investigative Site · York, United Kingdom
Show 3 removed
  • Novartis Investigative Site · Osaka, Japan
  • Novartis Investigative Site · Seoul, South Korea
  • Novartis Investigative Site · Seoul, South Korea
Nov 12, 2026
Primary completion
Dec 30, 2026→Feb 26, 2027
Nov 12, 2026
Study completion
Dec 30, 2026→Feb 26, 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    4 sites added, 3 sites removed
    Show 4 added (2 South Korea, 1 Japan, 1 United Kingdom)
    • Novartis Investigative Site · Osaka, Japan
    • Novartis Investigative Site · Seoul, South Korea
    • Novartis Investigative Site · Seoul, South Korea
    • Novartis Investigative Site · York, United Kingdom
    Show 3 removed
    • Novartis Investigative Site · Osaka, Japan
    • Novartis Investigative Site · Seoul, South Korea
    • Novartis Investigative Site · Seoul, South Korea
    Primary completion Dec 30, 2026→Feb 26, 2027
    Study completion Dec 30, 2026→Feb 26, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02962414
Responsible party
Sponsor
First posted
Nov 11, 2016
Start date
Aug 23, 2017
Primary completion
Feb 26, 2027 (estimated)
Completion
Feb 26, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion